However, clinical trials that target TNF-α with infliximab [Anti-TNF Therapy Against Congestive Heart Failure Trial (ATTACH)] or etanercept [Randomized Etanercept Worldwide Evaluation Trial (RENEWAL)] yielded disappointing results and were terminated prematurely due to poor survival improvement and enhanced risk of hospitalization (Chung et al., 2003; Mann et al., 2004). The gene discussed is TNF; the disease is congestive heart failure.